January 18, 2021
Bharat Biotech has said the company will pay compensation to
recipients in case of any serious adverse effects experienced
after receiving the antidote.
Bharat Biotech, which has received a government purchase order
for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine
In the consent form to be signed by the vaccine recipients,
Bharat Biotech said, "In case of any adverse events or serious
adverse events, you will be provided medically recognised standard
of care in the government designated and authorised centres/hospitals.
" "The compensation for serious adverse event will be paid by
sponsor (BBIL) in case if the SAE is proven to be causally
related to the vaccine," the consent form said.
In phase 1 and phase 2 clinical trials, Covaxin has demonstrated
the ability to produce antidotes against Covid-19.
However the clinical efficacy of the vaccine is yet to be
established and it is still being studied in phase 3 clinical
trials, the vaccine maker said.
"Hence it is important to appreciate that receiving the vaccine
does not mean that other precautions related to COVID-19 need
not be followed," the consent form said.
According to an industry expert, the company is liable to pay
compensation to people in case of serious side effects as the
vaccine is being administered while in the clinical trial
The central licensing authority has granted permission for the
sale or distribution of Covaxin for restricted use in emergency
situations in public interest as an abundant caution, in clinical
Meanwhile, Joint Managing Directorof BharatBiotech International
Ltd, SuchitraElla in her twitter account said, "Covaxin & Bharat
Biotech is truly humbled & honoured to be of service to the nation
& the fraternity of all first responders of covid who have served